




ADVENT

PIVOTAL TRIAL

**Recurrent Atrial
Arrhythmia Burden**



FARAPULSE™
Pulsed Field Ablation System

OBJECTIVE

- ▶ The ADVENT Pivotal Trial compared FARAPULSE™ Pulsed Field Ablation (PFA) to standard-of-care thermal ablation devices (force-sensing radiofrequency (RFA) or cryoballoon ablation (CBA)) and found no significant difference in 1-year freedom from atrial arrhythmias (AA) between groups.
- ▶ There is recent evidence that indicated post-ablation AA burden is a better predictor of clinical outcomes than the standard 30-second definition, so the recurrent AA burden was assessed to determine if it^{1,2}:
 - ▶ Impacted quality of life
 - ▶ Impacted healthcare utilization
 - ▶ Differed between ablation modalities

METHODS

- ▶ During ADVENT, post-ablation transtelephonic ECG monitoring (TTM) was collected weekly and for symptomatic episodes and 72-hour Holters were collected at 6- and 12-months.
- ▶ The TTM and Holter data was used to calculate the AA burden. Total AA burden was estimated by the greater of 2 values:
 - 1) % AA over total duration of Holter data or
 - 2) % of weeks of TTM with AA over total # of weeks with TTMs recorded
- ▶ Quality of life was assessed at baseline and 12-months.
- ▶ This sub-analysis included 593 (97.7%) patients.

ATRIAL ARRHYTHMIA BURDEN SUMMARY

- ▶ There was good overall compliance for weekly TTMs (67.5%) and 72-hour Holter monitoring (81.3%)¹.
- ▶ There was an average of 27 weeks of TTM from 589 patients and 61,841 hours of Holter recordings from 539 patients (average of 114.7 hours/patient).
- ▶ Most patients (465 (78.4%)) had an AA burden of <0.1%, which averaged to <1.4 minutes of AA/day.
- ▶ The aggregate patients with residual AA burden exceeding 10% was 47 (7.9%).

ATRIAL ARRHYTHMIA BURDEN, QUALITY OF LIFE

- ▶ Quality-of-life (QoL) AFEQT assessments were available from 287 PFA and 282 thermal patients.
- ▶ The aggregate data of both PFA and thermal patients was grouped by <0.1%, 0.1-9.9% and ≥10% post-ablation AA burden.
- ▶ There was a significant improvement in QoL, post-ablation, regardless of AA burden.
- ▶ **There was a significantly greater QoL improvement in patients with AA burden <0.1% versus ≥10%.**

ATRIAL ARRHYTHMIA BURDEN, CLINICAL INTERVENTIONS

- ▶ Clinical interventions were classified as redo ablations, cardioversions or hospitalizations.
- ▶ There was a low number of clinical interventions in the <0.1% AA burden patient cohort with a significant increase in frequency as AA burden increased.
- ▶ **There was a significantly lower risk for redo ablation, cardioversion and hospitalization with AA burden <0.1% vs. ≥0.1% (Table 1).**
- ▶ This data is consistent with other studies that patients with AA burden above 0.1% can expect significantly worse QoL and an increased need for clinical interventions.

Table 1	AA Burden		
	<0.1%	0.1-9.9%	≥10%
Redo Ablations	0.86%	11.1%	38.3%
Cardioversions	0.65%	9.9%	17.0%
Hospitalizations	1.72%	14.8%	42.6%

ATRIAL ARRHYTHMIA BURDEN, ABLATION MODALITY

- ▶ To assess the difference in ablation modality a threshold of 0.1% AA burden was used.
- ▶ There was a significant difference in AA burden between PFA, RFA and CBA with patients treated with PFA being more likely to have an AA burden <0.1% than patients treated with RFA or CBA (Figure 1).
- ▶ When AA burden between PFA and thermal was evaluated based on patient demographics, the only variable to show a significant difference in AA burden <0.1% was type of prior failed AAD(s).
- ▶ Patients with prior failed Class I/III AADs pre-ablation were more likely to have an AA burden <0.1% with PFA compared to thermal ablation. Class II/IV failed patients had no significant difference between ablation groups.




Figure 1. Post-Ablation Atrial Arrhythmia Burden Threshold of 0.1% by Ablation Modality.

CONCLUSIONS

- ▶ There was a significantly greater QoL improvement in patients with AA burden <0.1% and an increased risk for redo ablation, cardioversion and hospitalization in patients with >0.1% AA burden.
- ▶ Patients treated with FARAPULSE had a significantly greater reduction in AA burden (<0.1%) than patients treated with RFA or CBA which was found to be a clinically meaningful threshold.

1. Reddy VY, Gerstenfeld EP, Natale A, et al., Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation. *New England Journal of Medicine*. 2023;Nov2;389(18):1660-1671. doi:10.1056/NEJMoa2307291

2. Reddy V, Mansour M, Calkins H. et al., Pulsed Field vs Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation: Recurrent Atrial Arrhythmia Burden. *J Am Coll Cardiol*. null2024, 0 (0). <https://doi.org/10.1016/j.jacc.2024.05.001>



www.bostonscientific.eu

© 2024 Boston Scientific Corporation
or its affiliates. All rights reserved.

EP-1871419-AA

C € 0459

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.